Biosion, Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Holding, Joint Venture
- Established
- 2017-07-04
- Employees
- 51
- Market Cap
- -
- Website
- http://www.biosion.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- Biosion, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05932654
- Locations
- 🇺🇸
First OC Dermatology - Fountain Valley, Fountain Valley, California, United States
🇺🇸Center for Dermatology Clinical Research, Fremont, California, United States
🇺🇸Profound Research LLC - Nashville - Corporate, Oceanside, California, United States
Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Biosion, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT05114889
- Locations
- 🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia
News
OBI Pharma Initiates Phase 1/2 Trial for Novel TROP2-Targeted ADC OBI-902 in Advanced Solid Tumors
OBI Pharma has launched a Phase 1/2 clinical trial for OBI-902, the first antibody-drug conjugate utilizing their proprietary GlycOBI® ADC enabling technology platform.